Home Free and Complexed Prostate-Specific Antigen (PSA) in the Early Detection of Prostate Cancer
Article
Licensed
Unlicensed Requires Authentication

Free and Complexed Prostate-Specific Antigen (PSA) in the Early Detection of Prostate Cancer

  • Francisca Llinares Tello , Carmen Hernández Prats and María Dolores Dosdá González
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 39 Issue 2

Abstract

We evaluated the analytical performance and diagnostic utility of complexed prostate-specific antigen (CPSA) and their ratios, complexed-to-total PSA (C/T PSA) and free-to-complexed PSA (F/C PSA), in comparison with the total PSA (TPSA) and free-to-total PSA ratio (F/T PSA) as means of diagnosing prostate cancer (PC).

Samples (n=101) were drawn from men with no evidence of malignancy (n=80) and from men with PC (n=21) at biopsy. For determination of the F/T PSA ratio, the DPC® Immulite-2000 method was used; and the Bayer® Immuno-1 CPSA and TPSA assays were used to determine the C/T PSA ratio.

The Bayer® Immuno-1 CPSA assay provides accurate and precise CPSA values in human serum. The performance of the different forms and ratios was compared using receiver operating characteristic curve analysis. CPSA had the greatest area under the curve (AUC, 0.689) although it was not statistically different from the other parameters. A cut-off value of 4.66 ng/ml for CPSA provided a specificity of 38% and a sensitivity of 93%. The F/C PSA ratio maintained a sensitivity of 93% and had an increased specificity of 41%.

The measurement of CPSA provides a slight increase in specificity compared with the use of the TPSA in the early detection of prostate cancer.

:
Published Online: 2005-06-01
Published in Print: 2001-04-09

Copyright © 2001 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. Special Issues of the Journal
  2. Clinical Biological and Genetic Heterogeneity of the Inborn Errors of Pulmonary Surfactant Metabolism
  3. The Effects of Impaired Trace Element Status on Polymorphonuclear Leukocyte Activation in the Development of Vascular Complications in Type 2 Diabetes Mellitus
  4. Free and Complexed Prostate-Specific Antigen (PSA) in the Early Detection of Prostate Cancer
  5. Heterogeneity of DNA Methylation Status Analyzed by Bisulfite-PCR-SSCP and Correlation with Clinico-Pathological Characteristics in Colorectal Cancer
  6. Serum Amyloid A Protein (SAA) in Colorectal Carcinoma
  7. Metal Exposure from Amalgam Alters the Distribution of Trace Elements in Blood Cells and Plasma
  8. Diabetic Cataract and the Total Antioxidant Status in Aqueous Humor
  9. Candidate Gene Polymorphism in Cardiovascular Disease: A Comparative Study of Frequencies between a French and an Italian Population
  10. Reference Values for Plasma Dipeptidyl Peptidase IV Activity and Their Association with Other Laboratory Parameters
  11. Influence of Index of Individuality on False Positives in Repeated Sampling from Healthy Individuals
  12. Regional Reference Values for some Quantities Measured with the ADVIA Centaur Analyser. A Model of Co-operation between the In Vitro Diagnostic Industry and Clinical Laboratories
  13. Tissue Polypeptide-Specific Antigen (TPS) Concentrations in Cerebrospinal Fluid in Patients with Breast Cancer Metastases in the Central Nervous System
  14. The Measurement of Anti-Hepatitis C Virus Antibody in Sera Using a New Generation Immunoassay
  15. Quality Specifications for Cardiac Troponin Assays
  16. IFCC News January 2001
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2001.020/html
Scroll to top button